Preclinical ISAC 2
Undisclosed
PreclinicalAvailable for Partnering
Key Facts
About Bolt Biotherapeutics
Bolt Biotherapeutics is developing targeted immunotherapies based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which aims to harness the innate immune system to fight cancer. Founded in 2015 on foundational research from Stanford University, the company's strategy centers on advancing its lead clinical asset, BDC-4182, and leveraging collaborations to expand its pipeline. As a pre-revenue public company, Bolt faces the critical challenge of generating compelling clinical proof-of-concept data to validate its platform and attract further investment or partnership capital in a competitive oncology landscape.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |